The rise of Viagra and its influence on the pharmaceutical landscape presents a complex question for investors. While the first sales data were astounding, the patent has lapsed, leading to a wave of off-brand alternatives that are eroding earnings. Moreover, the sector is facing issues related to population trends and evolving healthcare regulatio